Abstract:Su Yuan, 1, 2 Biao Zuo, 2, 3 Si-Cong Zhou, 1, 2 Meng Wang, 2, 3 Kai-Yue Tan, 2, 3 Zhi-Wei Chen, 2, 3 Wen-Fu Cao 1– 3 1 Department of Combination of Chinese and Western Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China; 2 Chongqing Key Laboratory of Traditional Chinese Medicine for Prevention and Cure of Metabolic Diseases, Chongqing, People's Republic of China; 3 College of Traditional Chinese Medicine, Chongqing Medical University, Chongqing, People's Republic of China Correspondence: Wen-Fu Cao, The First Affiliated Hospital of Chongqing Medical University, No. 1, Youyi Road, Yuanjiagang, Yuzhong District, Chongqing, 400016, People's Republic of China, Email Purpose: Our study aims to reveal the pharmacological mechanism of Astragaloside IV in the treatment of pulmonary fibrosis(PF) through network pharmacology and experimental validation. Methods: We first determined the in vivo anti-pulmonary fibrosis effect of Astragaloside IV by HE, MASSON staining, and lung coefficients, then used network pharmacology to predict the signaling pathways and molecularly docked key pathway proteins, and finally validated the results by in vivo and in vitro experiments. Results: In in vivo experiments, we found that Astragaloside IV improved body weight (P < 0.05), increased lung coefficients (P < 0.05), and reduced lung inflammation and collagen deposition in mice with pulmonary fibrosis. The network pharmacology results showed that Astragaloside IV had 104 cross-targets with idiopathic pulmonary fibrosis, and the results of KEGG enrichment analysis indicated that cellular senescence could be an important pathway for Astragaloside IV in the treatment of pulmonary fibrosis. Astragaloside IV also bound well to senescence-associated proteins, according to molecular docking results. The results of both in vivo and in vitro experiments showed that Astragaloside IV significantly inhibited senescence protein markers such as P53, P21, and P16 and delayed cellular senescence (P < 0.05). In in vivo experiments, we also found that Astragaloside IV reduced the production of SASPs (P < 0.05), and in in vitro experiments, Astragaloside IV also reduced the production of ROS. In addition, by detecting epithelial-mesenchymal transition(EMT)-related marker protein expression, we also found that Astragaloside IV significantly inhibited the development of EMT in both in vivo and in vitro experiments (P < 0.05). Conclusion: Our research found that Astragaloside IV could alleviate bleomycin-induced PF by preventing cellular senescence and EMT. Keywords: astragaloside IV, pulmonary fibrosis, network pharmacology, cellular senescence, epithelial-mesenchymal transition Idiopathic pulmonary fibrosis (IPF) affects the lung parenchyma and is characterized by a decline in lung functions, abnormal deposition of extracellular matrix, and interstitial fibrosis that worsens with time. 1,2 The incidence of PF has been rising year after year in recent years; 3 however, IPF's onset and progression have complex mechanisms that are still unknown. 4–6 In addition to the recognized risk factors for IPF, such as smoke, environmental elements, comorbidities, and viral infections, various other processes are associated with the disease. Aging, epithelial-mesenchymal transition (EMT), endothelial-mesenchymal transfer, and epithelial cell migration are important factors in IPF-related tissue remodeling. 7 Pulmonary fibrosis (PF) is difficult to diagnose and incurable in the early stages and the prognosis is poor, with a 5-year survival <30% and an average survival time following diagnosis of 2–3 years. 8,9 Moreover, the incidence of PF is gradually increasing worldwide. 10 Nevertheless, there is a lack of effective drug therapy for IPF. Therefore, we need to urgently explore the exact molecular mechanisms of IPF progression for developing new therapeutic approaches. Astragaloside-IV (AS-IV) is a cycloartane triterpenoid and a key active compound of Astragalus . It exerts numerous medicinal uses, such as anti-inflammatory, antifibrotic, antiasthmatic, antidiabetic, and immunoregulatory through various signaling channels. 11 Current research and clinical experience indicate that AS-IV has a wide range of potential applications in several diseases. For instance, it slows the advancement of renal fibrosis by inhibiting the TGF-β/Smad signaling pathway. 12 In addition, AS-IV significantly delays the progression of liver fibrosis through the PAR2 signaling pathway -Abstract Truncated-

Astragaloside IV restores Th17/Treg balance via inhibiting CXCR4 to improve chronic obstructive pulmonary disease

Astragaloside Iv Improves Bleomycin-Induced Pulmonary Fibrosis in Rats by Attenuating Extracellular Matrix Deposition

Astragaloside IV Ameliorates Airway Inflammation in an Established Murine Model of Asthma by Inhibiting the Mtorc1 Signaling Pathway

Astragaloside IV suppresses inflammatory response via suppression of NF-κB, and MAPK signalling in human bronchial epithelial cells

Anti-Inflammatory Mechanism of Astragaloside IV in the Recurrence of Asthma: Critical Role of Memory T Cells and OX40/OX40L Signaling Pathway

Astragaloside IV alleviates PM2.5-induced lung injury in rats by modulating TLR4/MyD88/NF-κB signalling pathway

Astragaloside IV protects against lung injury and pulmonary fibrosis in COPD by targeting GTP-GDP domain of RAS and downregulating the RAS/RAF/FoxO signaling pathway

Astragaloside Ⅳ alleviates ulcerative colitis by regulating the balance of Th17/Treg cells

Astragaloside IV promotes the pyroptosis of airway smooth muscle cells in childhood asthma by suppressing HMGB1/RAGE axis to inactivate NF-κb pathway

Anemoside B4 prevents chronic obstructive pulmonary disease through alleviating cigarette smoke-induced inflammatory response and airway epithelial hyperplasia

Astragaloside IV targeting autophagy of T cells improves inflammation of asthma

N-Acetylcysteine Improves Inflammatory Response in COPD Patients by Regulating Th17/Treg Balance through Hypoxia Inducible Factor-1 α Pathway

Astragaloside IV ameliorates pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension by restraining the T follicular helper cell response and expanding T follicular regulatory cell response

Effect of Astragaloside on Diaphragm Cell Apoptosis in Chronic Obstructive Pulmonary Disease

Bu-Shen-Fang-Chuan Formula Attenuates T-lymphocytes Recruitment in the Lung of Rats with COPD Through Suppressing CXCL9/CXCL10/CXCL11-CXCR3 Axis

Astragaloside IV Inhibits Lung Injury and Fibrosis Induced by PM2.5 by Targeting RUNX1 Through miR-362-3p

Integrating Network Pharmacology and Experimental Validation to Explore the Pharmacological Mechanism of Astragaloside IV in Treating Bleomycin-Induced Pulmonary Fibrosis

Astragaloside IV improves pulmonary arterial hypertension by increasing the expression of CCN1 and activating the ERK1/2 pathway

Astragaloside IV inhibits progression of lung cancer by mediating immune function of Tregs and CTLs by interfering with IDO

Protective Effects of Astragaloside IV against Ovalbumin-Induced Lung Inflammation Are Regulated/Mediated by T-bet/GATA-3